The FDA approved crinecerfont (Crenessity) as a first-in-class treatment for classic congenital adrenal hyperplasia (CAH), the agency announced late Friday. Crinecerfont was approved for use in ...

Steroids, salt supplements, and birth control are some of the treatment options for this condition. Learn more about what they do and the potential side effects.

capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal ...

Sexual precocity and a testicular mass can result from a Leydig cell tumor or from simple virilizing CAH with adrenal rests in the testes. These diagnoses are usually distinguished by very high ...

Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. For more information about the Phase 2 TouCAHn study in classic CAH, please visit ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for the rare disorder that works by directly targeting the underlying ...

The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a ...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH ...

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH) study of investigational ...